STRIDER Consortium Sites
We have recruited 135 out of 135 patients to the STRIDER UK study!
STRIDER randomised controlled trial is designed to determine whether maternal treatment with oral sildenafil citrate improves perinatal outcomes in pregnancies complicated by severe early-onset IUGR without increasing risks to the mother.
The UBC group is co-ordinating an international consortium of independently funded STRIDER trials with an a priori planned individual participant data (IPD) meta-analysis at the conclusion of these trials. Currently, these trials are funded in New Zealand and Australia, United Kingdom, Ireland, the Netherlands and Canada. Each national trial will be performed using a shared protocol.
The primary outcome is post-randomisation abdominal circumference (by ultrasound) growth velocity (STRIDER NZAus), prolongation of pregnancy for one week as a surrogate for long-term morbidity (STRIDER UK and STRIDER Ireland), intact perinatal survival until term age (Dutch STRIDER), and gestation age at delivery (STRIDER Canada). After the trials have been completed, the IPD meta-analysis will have sufficient power for a hard perinatal survival outcome.